The Estée Lauder Companies Announces Retirement of Alexandra Trower, Executive Vice President, Global Communications
12.4.2021 14:00:00 EEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) (ELC) announced that after 13 years with the company, Alexandra (Alex) Trower, Executive Vice President, Global Communications, will retire effective July 1, 2021. The successor to Alex’s role will be announced at a later date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005450/en/
Alex Trower, Executive Vice President, Global Communications, The Estée Lauder Companies, announces retirement. (Photo: Business Wire)
“Alex has been a highly respected thought-leader, collaborative partner, and a trusted senior business advisor,” said Fabrizio Freda, President and CEO, The Estée Lauder Companies. “Leveraging her deep expertise across financial, corporate, consumer and crisis communications, Alex has continuously evolved our strategic communications priorities to drive and support the rapid growth of our business. She built a truly outstanding, global, multi-disciplinary organization and has led her team with wisdom and grace, continuously strengthening the delicate balance of art and science that is ever-present in the world of communications.”
William P. Lauder, Executive Chairman, The Estée Lauder Companies, added: “Against the backdrop of an increasingly complex global landscape, Alex has delivered thoughtful, effective communications to our valued stakeholders, strategically elevating our winning business narrative, rich culture, compelling heritage and distinctive ELC brand equity. She is an outstanding communicator and skilled strategist, and her incredible character, steadfast integrity and deep empathy will be greatly missed across the organization.”
Since joining The Estée Lauder Companies in 2008, Alex has been the architect of ELC’s Global Communications function as it stands today: a highly operationalized, flexible, worldwide and regional structure that prioritizes local relevance, functional expertise and brand-building acumen. Under her leadership, Global Communications has strategically expanded across regions; and through close partnership with regional and affiliate leaders, the department plays a critical role in supporting the company's continued strong regional growth.
Among her many accomplishments, Alex has strategically elevated the company’s reputation worldwide. In 2016, she oversaw the launch of the company’s refreshed Corporate Brand, which represented a transformational change in where, how and why the company engages with its stakeholders. Through this lens, Alex and her team have enabled the organization to communicate boldly, quickly and in more intentional and transparent ways, with an emphasis on strengthening and modernizing the platforms that most resonate with its audiences.
Alex has been a champion of ELC’s efforts across philanthropy, Citizenship and Sustainability, and Inclusion, Diversity and Equity. She serves as a Board member of The Estée Lauder Companies’ Charitable Foundation, is a founding member of the company’s Diversity Council, and served as the first Executive Co-Sponsor of wELCome, the company’s LGBTQA employee resource group.
Mentoring, leading and cultivating talented women is Alex’s passion, which was borne out of her experience as a student at Hollins University, one of the country’s leading women’s universities, where she now serves as the Chair of the Board of Trustees. In 2018, Alex was recognized by New York Women in Communications with a prestigious Matrix Award, presented to her by William P. Lauder in recognition of her exceptional leadership and contributions across the industry. She served as the Co-Chair of the Board of Directors for the International Women’s Media Foundation (IWMF), which supports female journalists worldwide. In 2014, she received the IWMF’s Corporate Leadership Award in recognition of her more than 15 years of service and fundraising.
“I am incredibly proud of all that my team and I have accomplished,” said Alex Trower. “ELC’s Global Communications organization has consistently advanced ahead of the curve, seamlessly partnering with stakeholders across the company and the industry to drive and support the continued success of our business. While the decision to retire is of course bittersweet, I know that the talented Global Communications team is well positioned for its next chapter of growth. On a personal note, it has been an absolute pleasure to serve in this role alongside the Lauder Family and the exceptional ELC executive leadership team.”
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.
ELC-L
ELC-C
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005450/en/
Contact information
Investor Relations:
Rainey Mancini
(212) 284-3049
Media Relations:
Jill Marvin
(212) 572-4438
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
